AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ROCKET PHARMACEUTICALS, INC. Director's Dealing 2022

Jun 16, 2022

33148_dirs_2022-06-15_7de5797a-9ac6-4320-b242-739cd6a53b32.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK: 0001281895
Period of Report: 2022-06-13

Reporting Person: SOUTHWELL DAVID P (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-13	Stock Option (Right to Buy)	$10.77	A	47745	Acquired	2032-06-13	Common Stock (47745)	Direct

Footnotes

F1: This option represents a right to purchase a total of 47,745 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 13, 2023.